Corneal allograft endothelial cell replacement represents a reparative response to transplant injury by Gong, Nianqiao et al.
Corneal allograft endothelial cell replacement represents a
reparative response to transplant injury
Nianqiao Gong,1 Uwe Pleyer,2 Thomas Ritter,3 Erich Knop,2 Xiaoping Chen1
1Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,
Wuhan, China; 2Department of Ophthalmology, Charité–University Medicine Berlin, Germany; 3Regenerative Medicine Institute,
National University of Ireland, Galway, Ireland
Purpose: To elucidate the injury of corneal allograft endothelial cells (ECs) upon rejection and the subsequent replacement
process of the cells.
Methods: The corneal transplantation model in an major histocompatibility complex (MHC) class I/II disparate Dark
Agouti (DA)-Lewis combination was used. The rejection kinetics was observed in 16 cases in which the corneal opacity
grade was recorded after grafting and after the onset of rejection. Four normal corneas and four allografts were subjected
to EC staining to investigate the EC integrity in cases of rejection. Furthermore, a series of rejected allografts were
examined and the EC integrity compared at one week, three weeks, three months, and six months after the onset of rejection.
Results: All corneal allografts were rejected, resulting in EC integrity loss. However, the allografts recovered transparency
around 18 days after the onset of rejection with repaired endothelium by regenerative ECs. Moreover, although the whole
endothelium would be fully recovered after rejection, the ratio of regenerative EC density reached only half of normal
levels as long as six months after the transplant.
Conclusions: Corneal allograft EC replacement represents a reparative response to transplant-related injury.
With more than 50,000 procedures per year in the US, the
cornea is the most commonly transplanted solid tissue [1-3].
An endothelial cell (EC) monolayer covers the inner side of
the endothelium, and its most important function is to pump
the infiltrating liquid out of the stroma and into the anterior
chamber to maintain corneal transparency. In cases of corneal
transplantation, immunological rejection remains one of the
main obstacles for a well functioning allograft, and ECs are
the critical target of rejection. The EC loss results in stroma
edema and a decrease of cornea graft transparency, which is
an indication of rejection onset.
For corneal allografts, although the EC monolayer is one
critical  compartment,  few  studies  have  focused  on  its
pathological response to rejection. One explanation is that the
opacity of rejected human corneas cannot be reversed [4], a
situation  which  prevents  researchers  from  carrying  out  a
sufficient investigation of the underlying pathophysiology.
But in some animal models, a return of corneal clarity has been
noted following rejection [5].
Although the interesting phenomenon of corneal allograft
transparency recovery has been observed, the EC regenerative
progress, including the absolute numbers of the cells and their
ratio in comparison with normal corneas, has not yet been fully
investigated.  In  the  present  study,  we  used  a  rat  corneal
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transplantation model to detail the kinetics of corneal allograft
EC replacement in the hopes of furthering our exploration into
corneal protective therapy.
METHODS
Animals: Inbred female rats of Dark Agouti (DA, RT.1Aav1)
and  Lewis  (RT.1A1)  strains  weighing  200–250  g  were
obtained from Charles-River (Kisslegg, Germany). Lewis rats
served  as  recipients  of  DA  grafts,  which  are  major
histocompatibility complex (MHC) class I/II disparate. All of
the  animals  were  housed  in  wire-bottomed  cages  with
controlled light/dark cycles, fed with a standard laboratory
diet, and given free access to tap water. Animals were handled
in accordance with the National Institute of Health “Guide for
the Care and Use of Laboratory Animals” and the German
guidelines on the use of animals in research (Title: Berliner
Senatsverwaltung).
Corneal  transplantation  and  definition  of  graft  rejection:
Orthotopic  corneal  transplantations  were  performed  as
reported  previously  [6,7].  Briefly,  all  animals  were
anaesthetized by an intramuscular injection of a mixture of
ketamine (90 mg/kg, Ketavet; Pharmacia GmbH, Erlangen,
Germany) and xylazine (7.5 mg/kg, Rompun 2%; Bayer Vital
GmbH, Leverkusen, Germany) diluted in saline during the
surgical procedure. Prior to surgery, 1% atropine sulfate drops
(Ciba Vision, Wefling, Germany) were topically applied to
dilate the pupil. The recipient and donor right cornea were
trephined with a 3.0 mm or 3.5 mm trephine, respectively, and
excised using Vannas scissors. The donor graft was sutured
into the recipient bed using a running suture (10–0 Mersilene;
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After  transplantation,  antibiotic  ointment  (Ofloxacin,
Floxal™;  Mann  Pharma,  Berlin,  Germany)  was  applied
immediately to the eye. Animals with surgical complications
such as intraocular hemorrhage or cataract were excluded.
Corneal opacity as an indicator of corneal endothelial function
and of graft endothelial injury was evaluated daily. Corneal
opacity  was  graded  as  follows:  0,  completely  transparent
cornea; 1, slight corneal opacity but iris vessels easily visible;
2,  moderate  corneal  opacity,  iris  vessels  still  visible;  3,
moderate  corneal  opacity,  only  pupil  margin  visible;  4,
complete corneal opacity, pupil not visible. Grades of 3 or
higher were diagnosed as rejection onset [6,7].
Experimental groups: First, 16 DA-Lewis transplants were in
one group for observation of rejection and recovery kinetics,
in which the corneal opacity grade was recorded daily after
grafting and rejection onset. We also employed an isograft
control group in which six Lewis-Lewis corneal transplants
were performed and the fate of the isografts was observed for
four weeks to identify if the allograft transparency decrease
was attributable to surgical trauma or alloimmune response.
To investigate the EC integrity under rejection, four normal
DA corneas, which were used as controls, were collected for
EC staining, and four additional grafts, which were diagnosed
as rejection onset, were also collected and stained. To clarify
EC replacement after rejection, another series of animals with
rejected grafts were housed. The animals were then divided
into four groups according to the different time points (one
week, three weeks, three months, six months) after rejection
onset when they were sacrificed for the graft EC integrity by
staining with four animals included in each group.
Recovery of corneal allograft opacity grade after rejection:
After  rejection  onset,  the  opacity  grade  of  the  corneal
allografts was recorded daily until all of them reached grade
0 in the 16 DA-Lewis transplants. The recovery duration (in
days) from rejection onset (grade 3 or 4) to grade 2 was
counted in each animal. The duration from rejection onset to
grade 0 (which means a full-functioning clear graft) was also
documented. The opacity grade was recorded again three and
six months after rejection onset.
Staining of corneal endothelial cell: Both corneal allografts
and  normal  corneas  were  harvested.  Analysis  of  DNA
fragmentation  (Terminal  deoxynucleotidyl  Transferase
Biotin-dUTP  Nick  End  Labeling  [TUNEL]  assay;
Boehringer, Mannheim, Germany) on the cornea button was
used for the staining of corneal endothelial cells. In brief, the
corneas  were  fixed  by  acetone  at  4  °C  for  10  min.  Fifty
microliters of TUNEL reaction mixture (2 μl enzyme solution
and  48  μl  label  solution)  was  added  to  each  sample  and
incubated in a humidified chamber for 60 min at 37 °C. A 50
μl converter peroxidase (POD) was then added to each sample
under the same conditions for 30 min. To develop the color,
a  50  μl  mixture  of  diaminobenzidine  (DAB)-substrate
solution was added to each sample and incubated for 5 min at
room temperature. Normal corneas were stained without any
enzyme solution and were used as the negative controls. The
staining was analyzed with a light microscope. ECs were
easily  identified  with  the  nuclear  staining.  Slight  brown
nuclear staining was seen as normal background and black
nuclear staining as positive apoptosis staining.
Endothelial cell distribution in normal corneas and rejected
allografts: The EC integrity in the normal corneas and rejected
transplants provides a baseline for further analysis of EC
alteration.  Four  normal  DA  corneas  and  four  allografts
diagnosed as rejection onset were collected and stained for
counting  cell  number  and  observing  cell  shape  and
distribution.
Regenerative  endothelial  cells  recovering  the  graft
endothelium following rejection onset: Four corneal allografts
at each different time point (one week, three weeks, three
months, and six months after rejection onset) were collected
for  EC  staining.  The  recovered  area  was  evaluated  by
percentage to describe the reparative process. The EC density
was calculated by numbers/mm2, and cell ratio (allograft to
normal DA cornea) was expressed as a percentage.
Statistical analysis: Graft survival was presented as median
±standard  error  (MST)  using  the  Kaplan–Meier  survival
method.  The  other  data  were  calculated  using  Statistical
Package  for  the  Social  Science  (SPSS)  11.0  (SPSS  Int.,
Chicago,  Illinois)  by  one-way  ANOVA  and  χ2  test.  A
statistically significant difference was defined as p<0.05 .
RESULTS
All  Lewis  recipients  rejected  their  Dark  Agouti  corneal
allografts featured with endothelial cell loss: To investigate
the rejection kinetics of the MHC class I/II disparate DA-
Lewis corneal transplant, 16 Lewis rats were employed as the
recipients of DA corneal grafts. No treatment was given to
either the donors or the recipients. During the first week after
transplantation, the grafts had slight stroma edema but then
recovered clarity within one week. Afterward, their opacity
grade increased gradually to 3 or 4, which was defined as
rejection onset. The rejection kinetics of these allografts is
shown in Figure 1A. The rejection happened in all allografts
from day 11 to day 14 (MST 13.1±0.3 days, n=16). In the
isograft  control  group,  except  when  the  slight  edema
happened  due  to  surgical  trauma,  all  transplants  retained
clarity in the observation of four weeks, showing that the
opacity grade increase was attributable to the immunological
response.
To  clarify  the  integrity  of  the  allograft  ECs  under
rejection,  four  normal  DA  corneas  and  four  additional
allografts  on  the  day  of  rejection  were  collected  for  EC
staining.  The  staining  photos  are  shown  in  Figure  1B,C,
respectively.  The  ECs  were  distributed  regularly  on  the
normal  cornea  endothelium.  In  contrast,  all  ECs  on  the
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655Figure 1. The effect of rejection upon
corneal  allografts.  A:  The  rejection
kinetics of corneal transplantation in the
DA-Lewis  combination  is  shown.
Sixteen Lewis rats served as recipients
of DA allografts. The opacity grade 3 or
4  is  defined  as  rejection  onset.  The
rejection happened in all allografts from
day  11  to  day  14  with  an  MST  of
13.1±0.3 days (n=16). Meanwhile, no
rejection  was  observed  in  any  of  the
isografts (n=6). B: The EC staining in a
normal  DA  cornea  is  displayed.  The
cells  were  distributed  regularly,  and
their  nuclei  exhibited  similar  shape
(magnification  400X).  C:  The  EC
staining in rejected corneal allograft is
shown.  All  ECs  were  lost  except  the
remaining apoptotic cell (400X).
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cells.
Corneal  allograft  transparency  gradually  recovered  after
rejection onset: We continued our observation of the graft
opacity after rejection among the 16 animals. It was a constant
phenomenon  that  all  of  the  grafts  would  recover  clarity
gradually from grade 4/3 back to grade 0, which indicated a
well functioning EC layer covering the endothelium. Among
all 16 animals, the longest time for clarity recovery took 22
days. The alteration of opacity grade of these allografts was
shown in Figure 2. The opacity grade of the transplants was
recorded daily for 22 days after rejection, and the numbers of
transplants  with  opacity  grade  4/3  (rejection),  2/1
(recovering), and 0 (recovered) used to document the recovery
process were also recorded. From rejection onset to grade 2
(a key step indicating the beginning of function recovery), the
duration was 8.9±4.1 days. From rejection onset to grade 0
(full-functioning), the duration was 18.3±2.2 days. Once the
opacity grade had recovered, the cornea maintained stable
clarity during the whole observation up to six months.
Corneal allografts with recovered transparency were covered
by newly generated endothelial cells: Our above mentioned
data prove that rejection results in losing all of the graft ECs.
To further identify the EC status on graft endothelium after
rejection, a series of rejected grafts from different time points
(one week, three weeks, three months, and six months after
rejection onset) were collected for staining. One week after
rejection onset, ECs were detected covering part of the graft
endothelium  (Figure  3,  A1,A2)  while  the  corneal  opacity
grade was decreasing. Three weeks after rejection, the whole
endothelium was covered by ECs, although the distribution
and cell nuclear shape were not as regular as they normally
would be and the amount was also less than normal (Figure 3,
B1,B2,B3,B4). The opacity grade reached 0 or 1, indicating
full EC layer function for the cornea. Three months and six
months after surgery, the corneas retained clarity and had a
relatively intact EC layer (Figure 3, C1,C2), although not yet
to the same extent as the normal corneas (Figure 1B).
The regenerative endothelial cells repaired the transplant
injury but presented a density less than normal: We then
analyzed the regenerative EC’s distribution at different time
points after rejection onset. By staining the series of rejected
grafts at different time points (one week, three weeks, three
months, and six months), the percentage of the endothelium
covered area was calculated. They were 31%, 100%, 100%,
and 100% at one week, three weeks, three months, and six
months,  respectively  (Figure  3,  A1,B1,C1,C2,  and  Figure
4A). Furthermore, EC density of the normal DA corneas and
corneal  allografts  were  calculated  and  compared.  In  the
normal corneas, the EC density was 2882/mm2 while it was
940/mm2,  1376/mm2,  1530/mm2,  and  1608/mm2  in  the
allografts at one week, three weeks, three months, and six
months after rejection onset, respectively. The EC densities
were 32.6%, 47.8%, 53.1%, and 55.8% of the normal level at
one  week,  three  weeks,  three  months  and  six  months,
respectively, as shown in Figure 4B.
DISCUSSION
According  to  their  species,  the  corneal  allografts  exhibit
different outcomes in response to rejection. Human corneal
EC loss leads to graft failure in clinic while in mice, 50%–
60% of recipients do not undergo any rejection. To find clues
for  promoting  the  efficacy  of  human  allografts,  a  stable
corneal  rejection  model  is  needed  to  investigate  the
underlying mechanism of rejection and graft opacity. In the
present study, we introduced the DA-Lewis combination in
which  all  grafts  were  rejected  within  two  weeks  of
transplantation as shown in Figure 1A. The rejection was
diagnosed by a marked increase of opacity grade, an indicator
that has been adopted widely in this study area [8-10]. To
further  verify  if  the  allograft  opacity  was  indeed  due  to
rejection, we used one isograft group as the control, which
excluded  the  influence  of  immunological  factors,  and  the
result  showed  that  the  surgical  trauma  only  induced  a
temporary slight edema after a successful surgery.
In this study, rejection destroyed the whole EC layer
(Figure 1B) so that donor ECs did not exist afterward and the
Figure  2.  Recovery  process  of  the
corneal  allograft  transparency  after
rejection  onset.  Following  rejection
onset,  the  number  of  allografts  was
documented until all of them regained
completely clarity up to 22 days based
on their opacity grade. Grade 4/3 (black)
represents  grafts  rejected,  grade  2/1
(gray) represents grafts recovering, and
grade  0  (blank)  represents  grafts
recovered.
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657Figure 3. The process of corneal allograft EC replacement following rejection. A: The DA corneal allograft EC staining one week after rejection
onset is displayed. ECs were covering part of the graft endothelium (A1; magnification 100X). The arrows show that the immigrating cells
were crawling across the suture.ECs were covering part of the graft endothelium (A2; 400X). B: The DA corneal allograft EC staining three
weeks after rejection onset is shown. The whole endothelium was covered by ECs where the distribution and cell nucleus shape were not as
regular and the cell number was less than the normal level (B1-B3). The triangle shows a germinal center-like structure (B1,100X; B2: 200X;
B3: 400X). The bold arrow shows the cells were growing radially with an active proliferation state (B4; 100X). C: The DA corneal allograft
EC staining three and six months after rejection onset is displayed. Three months after rejection onset, a relatively intact ECs layer is shown,
although not yet perfect (C1; 100X). Six months after rejection onset, a relatively intact EC layer was shown (C2; 100X).
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658corneal  transplants  became  opaque.  But  interestingly,  the
graft transparency recovered gradually. First, the grafts began
to  regain  clarity  around  one  week  after  rejection,  a  fact
established  by  the  observation  that  the  opacity  grade
decreased to 2. Then, the grafts reached total transparency
around  18  days  after  rejection.  The  time  to  transparency
recovery  represents  a  process  of  endothelium  repair.  An
extended observation of up to six months showed that this
recovery exhibited a stable status, indicating that the corneal
structure was reconstructed with full function.
We  then  checked  the  EC  status  in  the  process  of
transparency return and found that the dynamics of the EC
recovery were time-dependent. One week after rejection, the
regenerative  ECs  covered  one-third  of  the  area  of  the
endothelium  with  a  similar  value  of  EC  density  ratio.
Meanwhile,  the  graft  function  obtained  a  substantial
improvement from opaque to opacity grade 2. From the time
point  of  three  weeks  after  rejection,  the  graft  recovered
transparency, and the endothelium was fully recovered in the
whole observation up to six months. However, the EC density
showed  an  increase  inconsistent  with  the  area  recovery,
exhibiting only half the level of the normal even up to six
months after rejection onset. Meanwhile, these ECs exhibited
irregular  features  in  both  their  cell  morphology  and
distribution. Subtler factors influencing the EC regeneration
and  proliferation  and  the  reparative  response  against  the
transplant-related injury must surely exist, a consideration that
should be further explored.
It is likely that the regenerative ECs developed mainly
from the host endothelium. First, the allograft ECs were lost
due  to  rejection,  therefore  no  donor-derivation  existed  as
shown in Figure 1C. Furthermore, the staining results showed
three  interesting  histological  observations.  First,  the
proliferating cells were crawling across the suture as shown
in  Figure  3,  A1.  Second,  the  proliferating  cells  located
together  to  generate  a  germinal  center-like  structure  with
irregular  nuclear  size  (Figure  3,  B1,B2,B3).  Third,  the
proliferating cells were growing radially, indicating an active
proliferation state as shown in Figure 3, B4. Although without
direct  MHC  haplotype  evidence,  it  is  suggested  that  the
regenerative  cells  are  developed  from  the  host’s  adjacent
corneal endothelium. In other solid organ allografts, it has
been hypothesized that EC precursors are recruited from a
variety of sources depending on the severity and duration of
injury. During limited damage, neighboring ECs will provide
sufficient repair potential. More severe damage may signal in-
growth of ECs from adjacent host tissue, and severe damage
with  a  full  rupture  of  layers  will  lead  to  recruitment  via
circulation  [11-13].  In  this  case,  corneal  allograft  EC
reparative response shows its own features related to its severe
damage  and  cell  derivation  more  so  than  other  solid
transplants.
Figure 4. The kinetics of regenerative
ECs covering the endothelium. A: The
percentage of endothelium covered area
at different time points after rejection
onset is shown in the chart. The area of
recovered endothelium was calculated
after  one  week,  three  weeks,  three
months,  and  six  months.  From  three
weeks  after  rejection  onset,  the
recovered  area  reached  100%  of  the
normal  level.  B:  The  density  and
percentage  of  the  regenerative  ECs
compared with normal cornea is shown
in the second chart. The EC density of a
normal DA cornea is 2882/mm2. At the
different  time  points,  the  density  and
percentage of the regenerative ECs were
calculated.  The  density  of  the
regenerative  ECs  was  32.6%  of  the
normal level at one week after rejection
onset,  and  then  gradually  improved.
However,  inconsistent  with  the  area
recovery,  the  density  reached  only
55.8%  of  the  normal  level  up  to  6
months after rejection onset.
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replacement is valuable because it not only influences our
understanding  of  graft  characteristics  but  also  helps  in
determining effective treatment approaches for protecting the
graft.  After  transplantation,  frequent  therapy  is  the  main
means  used  to  protect  the  graft  and/or  modulate  immune
response,  a  practice  which  could  alter  graft  EC  origin
[14-16]. However, there has until now been no treatment in
clinics for the lost transparency induced by rejection. We had
transferred  graft-protective,  adenovirus-mediated  nerve
growth factor into the allograft ECs before transplantation in
the  rat  model,  which  diminished  the  expression  of  pro-
inflammatory  cytokines,  increased  the  expression  of  anti-
apoptotic  molecules,  prolonged  the  graft  survival
significantly,  and  even  resulted  in  zero  rejection  in  some
transplants that retained transparency. Furthermore, no cell in
growth from the adjacent area was found at day 12 after the
transplant and only a small proportion of ECs was lost [8].
The results encourage further study on corneal allograft EC
repair and protection.
Our findings could contribute to establishing a proper
direction for corneal therapy such as enhancing the reparative
response and generating a functioning EC monolayer through
the initiation of proliferation and replacement of host-derived
ECs, protection of graft ECs, or building EC chimerism of
graft and recipient. Since corneas can be stored ex vivo for a
relatively  long  time  before  transplant,  preconditioning
treatment to protect the ECs to construct an accommodation
status  by  using  therapy  such  as  local  therapeutic  gene
transfection is one option [8,17]. Furthermore, the corneal
graft is easily accessed following the operation so that topical
treatment initiating EC chimerism or replacement could be
applied locally not only on the graft but also on the recipient.
In  conclusion,  corneal  allograft  EC  replacement
represents a reparative response to transplant-related injury
rather than a constant mechanism of tissue maintenance that
depends  on  the  regenerative  features  of  ECs.  These  new
findings should be beneficial for developing new strategies
for corneal therapy.
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